Samuel Singer

Vincent Astor Chair of Clinical Research

Memorial Sloan Kettering Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (50)

Purpose: The CDK4/6 inhibitor palbociclib delays progression in patients with advanced dedifferentiated liposarcoma (DDLPS). In carcinoma models, CDK4/6 and PD-1 inhibition induce intratumoral inflammation and synergistic activity. Comprehensive assessment of tumor and host dynamics is needed to understand response and resistance to this combination. Patients and Methods: We performed a phase 2 study of palbociclib and the PD-1 inhibitor retifanlimab in advanced DDLPS. Palbociclib was administered 2 weeks prior to retifanlimab. Tumor biopsies were analyzed by single-cell RNA sequencing (scRNA-seq), and peripheral blood by high-parameter flow cytometry. Analyses focused on cell cycle, senescence, and immune-related changes. Results: Twelve patients were treated before the study was halted because of a 42% immune-related toxicity rate. The overall response rate was 8.3%, and the disease control rate was 75%. Median progression-free and overall survival rates were 7.1 and 26.8 months, respectively. Nine patients had at least one tumor biopsy analyzed; three had paired. Ten patients had paired blood samples analyzed. Following treatment, tumor cells demonstrated decreased cycling and increased cell-cycle checkpoint activity. Transcriptional scores for senescence increased in cancer cells, as did the proportion of intratumoral T and B cells. A cluster of cells emerged with upregulated cell-cycle genes and downregulated HLA class I, suggesting innate or acquired resistance to treatment. In blood, a subset of CD4 + T cells decreased, whereas expression of LAG-3, ICOS, and CD38 increased in select subsets. Conclusions: A palbociclib lead-in prior to retifanlimab had a high rate of immune-related toxicities. Correlative analyses identified changes in tumor and immune cells attributable to treatment. A study of concurrent dosing of the combination is ongoing. Significance: In this phase 2 study of palbociclib and retifanlimab, treatment led to immune-related adverse events, halting enrollment. scRNA-seq and flow cytometry revealed cell-cycle suppression, senescence, and T-cell changes. These findings highlight the rationale for this combination and the need for safer dosing strategies in larger cohorts.

Year:

2026

Changes in tumor and immune cell populations and phenotypes with anti–PD-1. A, CDK4 and MDM2 expression in tumor cells according to best response. PD, P03, before and after retifanlimab initiation (IO); SD, three before IO and six after IO. B, Signature scores in tumor cells according to best response. Same samples as in A . C, Integrated clustering of cancer cells from patients with paired samples and sufficient tumor fraction. D and E, Intracluster signature score changes with initiation of retifanlimab, plotted ( D ) along the x -axis or ( E ) as dot size. F , Volcano plot of differential expression of genes related to immune response in cluster 8 vs. all other clusters from P12.

Year:

2026

Changes in proportions of T-cell populations with anti–PD-1 via high-parameter flow cytometry. A, Change in abundance of T-cell subtypes with initiation of retifanlimab in patients with paired biopsies and detectable tumor-infiltrating T cells. B, Boxplot depicting percent change post- vs. pre-retifanlimab in the abundance of 63 T cell types. Filled boxes with bold labels and asterisks indicate T cell subsets with significant changes ( P C and D, Percent change in four key subsets of ( C ) CD4 + and ( D ) CD8 + T cells. OR, overall response.

Year:

2026

Clinical trial design and efficacy. A, Study schema depicting treatment and biopsy collection time points. B, Flow diagram of treatment and follow-up for patients in the safety lead-in and trial expansion cohorts. C, Waterfall plot showing best percent tumor volume change from baseline per RECIST 1.1. One patient who was not evaluable for response by RECIST 1.1 is excluded. irAE(+), solid circles indicate irAEs; SC+, single-cell data from tumor biopsies, in which filling of the left and right halves indicates analyzability at the pre- and post-retifanlimab time points, respectively. D, Spider plot showing percent change in sum of target lesion diameters over time in patients who were evaluable for response by RECIST v1.1. E, Swimmer plot showing patient PFS. Dashed line indicates median PFS. NE, not evaluable; OR, overall response.

Year:

2026

Overview of scRNA-seq data. A, Cell clustering by UMAP. B, Expression of key markers within major cell populations, pooled among all specimens. C, Cell type proportion in each patient. Patients with paired biopsies were merged. D, Comparison of cell type proportions before vs. after retifanlimab initiation (IO) in patients with paired biopsies. UMAP, Uniform Manifold Approximation and Projection.

Year:

2026

Genetically engineered mouse models (GEMM) of cancer are useful for exploring the development and biological composition of human tumors. Single-cell RNA sequencing (scRNA-seq) provides a transcriptomic snapshot of cancer to explore the heterogeneity of cell states in an immunocompetent context. However, cross-species comparison often suffers from biological batch effect, and inherent differences between species decrease the signal of biological insights that can be gleaned from these models. In this study, we developed scVital, a computational tool that uses a variational autoencoder and discriminator to embed scRNA-seq data into a species-agnostic latent space to overcome batch effect and identify cell states shared between species. In addition, latent space similarity score was concurrently developed as a new metric to evaluate batch correction accuracy by leveraging prelabeled clusters for scoring instead of the current method of creating new clusters. Using latent space similarity for quantification, scVital performed comparably well relative to other deep-learning algorithms and rapidly integrated scRNA-seq data of normal tissues across species with high fidelity. When scVital was applied to pancreatic ductal adenocarcinoma or lung adenocarcinoma data from GEMMs and primary patient samples, scVital accurately aligned biologically similar cell states. In undifferentiated pleomorphic sarcoma, a test case with no a priori knowledge of cell state concordance between mouse and human, scVital identified a previously unknown cell state that persisted after chemotherapy and is shared by a GEMM and human patient-derived xenografts. These findings establish the utility of scVital in identifying conserved cell states across species to enhance the translational capabilities of mouse models. Significance: ScVital is an algorithm for cross-species integration of single-cell data to identify common cell states and facilitate translation of tumor models towards therapeutic application. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .

Year:

2026

Supplementary Figure 1. Traditional risk stratification in primary gastric and small bowel GIST. Primary gastric (A-C) and small bowel (D-F) GISTs localized at diagnosis without prior neoadjuvant treatment are risk stratified into low, moderate, and high risk groups based on site, tumor size and mitotic rate using the Miettinen (also includes very low risk) (A, D), Fletcher (B, E) and Joensuu (C, F) risk stratification schemes (Miettinen 2006, Fletcher 2002, Joensuu 2008). Recurrence-free survival for patients in each of these risk groups is represented by Kaplan-Meier curves (global log-rank P) for all primary localized cases.

Year:

2025

Supplementary Table S1. Metastasis Frequencies by Traditional vs. Genomic Risk Stratification Supplementary Table S2. List of gene level and chromosomal arm level genomic variables used in OncoCast. Supplementary Table S3-S4. Frequencies of genomic alterations by OncoCast risk groups in primary gastric and small bowel GISTs. Supplementary Table S5. Number and frequencies of specific KIT/PDGFRA mutations in primary localized gastric and small bowel GISTs.

Year:

2025

Supplementary Figure S4. RFS in primary localized gastric (A) and small bowel (B) GISTs by types of primary KIT and PDGFRA mutations [del: deletion; ex: exon; INS: insertion; PM: point mutation].

Year:

2025

Purpose: This study investigated factors that affected ctDNA detection and ctDNA as a molecular biomarker in a phase II trial of imatinib and binimetinib in newly diagnosed advanced gastrointestinal stromal tumor, including patients exposed to imatinib within 4 weeks of trial enrollment. Experimental Design: Plasma and tumor tissue samples were collected at baseline, during treatment, and upon progression. DNAs extracted from plasma and tumor tissue were analyzed using genomic assays, Memorial Sloan Kettering Analysis of Circulating cfDNA to Evaluate Somatic Status and Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets, respectively. Sequenced ctDNA detection of the primary oncogenic driver was determined and correlated with clinical characteristics. Results: Patients ( n = 31) included in this analysis had KIT mutations ( n = 29, 94%) and metastatic disease ( n = 24, 77%) and achieved the best response of partial response ( n = 22, 71%), stable disease ( n = 8, 26%), or progressive disease ( n = 1, 3%). Sixteen patients (52%) were exposed to imatinib at baseline. The ctDNA detection rate of the primary oncogenic driver at baseline was 39% ( n = 12/31) and was significantly more likely in patients who were treatment-naïve ( n = 15) or had ≤4.2 weeks of treatment ( n = 8) than in those otherwise (48% vs. 13%; P value = 0.004). Baseline ctDNA detection did not correlate with tumor burden or stage. The ctDNA serial analysis of the primary oncogenic driver paralleled and sometimes preceded radiographic response. ctDNA detected resistance mutations in KIT ( n = 4). Active treatment influenced the detection of secondary KIT alterations in one patient. Conclusions: Active therapy at the time of ctDNA collection negatively affected the ability to detect primary and secondary KIT alterations in sequenced ctDNA from patients with advanced gastrointestinal stromal tumor. ctDNA responses may precede radiographic responses and merit further investigation.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (17)

Doron Betel

Associate Professor

Weill Cornell Medicine

UNITED STATES
View details

Mark A. Dickson

-

UNITED STATES
View details

Raghu Kataru

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Nguan Soon Tan

Professor

Nanyang Technological University (NTU)

SINGAPORE
View details

Rodrigo Gularte Mérida

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Sam S. Yoon

-

UNITED STATES
View details

Josephine Kam Tai Dermawan

Associate Staff

Cleveland Clinic

UNITED STATES
View details

Rachael O'Connor

Sloan Kettering Institute

UNITED STATES
View details

Benjamin A Nacev

University of Pittsburgh

UNITED STATES
View details

Robert G. Maki

Professor, Member

-

UNITED STATES
View details

Jason Chan

Cedars-Sinai Medical Center

UNITED STATES
View details

Ciara Kelly

-

UNITED STATES
View details

Jonathan Rub

Victor Chang Cardiac Research Institute

AUSTRALIA
View details

Marta Kovatcheva

Group Leader (Assistant Professor Equivalent)

IFOM – The AIRC Institute of Molecular Oncology

ITALY
View details

Andrew Koff

Sloan Kettering Institute

UNITED STATES
View details

Edmund Bartlett

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Violeta Serra

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details